US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Guidance Targets ‘Multiplicity Problem’
Executive Summary
Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.